1. The effects of dicyclohexylcarbodi-imide, oligomycin A and aurovertin on enzyme systems related to respiratory-chain phosphorylation were compared. Dicyclohexylcarbodi-imide and oligomycin A have very similar functional effects, giving 50% inhibition of ATP-utilizing and ATP-generating systems at concentrations below 0.8nmole/mg. of submitochondrial-particle protein. Aurovertin is a more potent inhibitor of ATP synthesis, giving 50% inhibition at 0.2nmole/mg. ofprotein. However, aurovertin is a less potent inhibitor ofATP-utilizing systems:
1. The effects of dicyclohexylcarbodi-imide, oligomycin A and aurovertin on enzyme systems related to respiratory-chain phosphorylation were compared. Dicyclohexylcarbodi-imide and oligomycin A have very similar functional effects, giving 50% inhibition of ATP-utilizing and ATP-generating systems at concentrations below 0.8nmole/mg. of submitochondrial-particle protein. Aurovertin is a more potent inhibitor of ATP synthesis, giving 50% inhibition at 0.2nmole/mg. ofprotein. However, aurovertin is a less potent inhibitor ofATP-utilizing systems:
the ATP-driven energy-linked nicotinamide nucleotide transhydrogenase is 50% inhibited at 3*Onmoles/mg. of protein and the ATP-driven reduction of NAD+ by succinate is 50% inhibited at 0.95nmole/mg. of protein. 2. With EDTA-particles (prepared by subjecting mitochondria to ultrasonic radiation at pH 9 in the presence of 2mM-EDTA) the maximum stimulation of the ATP-driven partial reactions is effected by similar concentrations of oligomycin A and dicylcohexylcarbodi-imide, but the latter is less effective. The stimulatory effects of suboptimum concentrations of dicyclohexylcarbodi-imide and oligomycin A are additive. Aurovertin does not stimulate these reactions or interfere with the stimulation by the other inhibitors. 3. Dicyclohexylcarbodi-imide and oligomycin A stimulate the aerobic energy-linked nicotinamide nucleotide transhydrogenase ofEDTA-particles, butthe optimum concentration is higher than that required for the ATP-driven partial reactions. Aurovertin has no effect on this reaction. 4. The site of action of dicyclohexylcarbodi-imide is in CFo, the mitochondrial fraction that confers oligomycin sensitivity on F1 mitochondrial adenosine triphosphatase.
Aurovertin, DCCD$ and the oligomycins A, B, C and D (rutamycin) have been shown to inhibit the synthesis of ATP associated with mitochondrial electron transport (Lardy, Connelly & Johnson, 1964; Lardy, Johnson & McMurray, 1958; Lardy, Witonsky & Johnson, 1965) , and alsotoinhibit those partial reactions of oxidative phosphorylation that are driven by ATP, e.g. ATP-driven reduction of NAD+ by succinate, ATP-driven energy-linked nicotinamide nucleotide transhydrogenase, uncoupler- (Lenaz, 1965) (this might explain the findings of Lardy et al. 1964, above) , (2) aurovertin is unable to stimulate energy-linked reactions in EDTAparticles and (3) aurovertin does not inhibit NADH oxidase activity in EDTA-particles. Further support for this location of aurovertin action comes from the finding that aurovertin inhibits the ATPase activity of the coupling factor, F1, which is thought to catalyse the terminal reaction of oxidative phosphorylation (Kagawa & Racker, 1966a; Roberton, Beechey, Holloway & Knight, 1967) , and from the unpublished work of H. A. Lardy & B. Chance (quoted by Ernster et al. 1967 ) that aurovertin combines with and inhibits F1.
In this paper we have compared quantitatively the amounts ofaurovertin, DCCD and oligomycin A required to inhibit various energy-linked reactions in an attempt to establish whether they act at the same or different sites. The hypothetical mechanism proposed for the reaction sequence that they inhibit is discussed.
METHODS
Molecular weights of inhibitors. The molecular formulae and molecular weights of the three inhibitors used in this study are as follows: aurovertin, mol. wt. 476, formula C25H3209; DCCD, mol. wt. 206, formula C13H22N2;  oligomycin A, mol. wt. 446, formula C28H4604 (Beechey, Williams, Holloway, Knight & Roberton, 1967b) .
Methods of addition of inhibitors. The inhibitors were dissolved in either ethanol or dimethylformamide. Samples of oligomycin A and aurovertin were added to the assay system containing mitochondrial protein 3min. before the final addition of a substrate. Samples of DCCD were added to suspensions of mitochondrial protein 16-24hr. before assays were carried out. At the end of this preincubation at 00, a sample of mitochondrial protein containing DCCD was pipetted into the assay system followed after 3 min. by substrate (Beechey et al. 1967a ). Assays. The conditions for assay of respiration rates, ATP-driven reduction of NAD+ by succinate, ATP-driven energy-linked nicotinamide nucleotide transhydrogenase, aerobically driven energy-linked nicotinamide nucleotide transhydrogenase and non-energy-linked nicotinamide nucleotide transhydrogenase have been described by Beechey et al. (1967a) . The ATPase assay used was based on the method of . Assay conditions are described in the legends to the Tables and Figures. Preparation of mitochondria, SMIP and EDTA-particles.
The preparation of mitochondria and SMP from ox heart has been described by Beechey et al. (1967a) . EDTAparticles were prepared by the method of Lee, Azzone & Ernster (1964) from HBHM. The HBHM had been prepared the previous day either by the Nagarse proteinase method described by Beinert (1964) or by the blender method of Sanadi & Fluharty (1963) , and had been stored in 0 25m-sucrose-10mm-tris sulphate buffer, pH7-7, at 00 overnight. EDTA was added to a final concentration of 2mm and the pH was adjusted to 9. The mitochondrial suspension was then subjected to ultrasonic radiation. The resulting submitochondrial particles, EDTA-particles, were isolated by differential centrifugation. They were suspended in a solution containing 0 25M-sucrose-10mM-tris sulphate buffer, pH 7-7. Cytochrome a+a3 estimation. A solution containing SMP (10-15mg. of protein), 10,g. of antimycin A, 300,umoles of tris sulphate buffer, pH7-6, and 15mg. of sodium cholate was made up to 3ml. with water at room temperature (Blair, Oda, Green & Fernandez-Moran, 1963) . The solution was divided equally between two 1 cm.-light-path spectrophotometer cells, and a difference spectrum was recorded from 630mg to 605m,u before and after the addition of Na2S204 to one cell. A Cary 14 recording spectrophotometer was used with a 0-0-1 extinction slidewire. The difference in extinction at 605 m, was measured assuming that the extinction at 630m, was unaffected by the addition of Na2S204. The haem a content in the cytochrome a+ a3 was calculated on the basis of AE,m, (reduced minus oxidized) at 605m,u 12O0cm.2/4mole (Van Gelder & Slater, 1963 (1967) . It was stored in 50% (v/v) glycerol at -20°until used. During the preparation, one half of the supernatant material obtained after centrifugation of the homogenized acetone-dried powder was treated overnight with 5 nmole of DCCD/mg. of protein at room temperature. This material was then fractionated with (NH4)2SO4, as was the control material.
Preparation of CFo. CFo was prepared by the method of Kagawa & Racker (1966b) . At the T-particle stage of the preparation, one half of the material was treated overnight with 5nmoles of DCCD/mg. of protein and subsequently fractionated in the same way as the control material.
RESULTS
Effect of inhibitors onADP-stimulated respiration. The concentrations of inhibitors required to inhibit ADP-stimulated respiration in HBHM(N) are shown in Fig. 1 In each assay 1-12mg. of protein of SMP was used. DCCD was preincubated overnight with the SMP. Aurovertin and oligomycin A were incubated with the SMP in the assay cuvette for 3min.; then NADP+ was added, followed 1 min. later by ATP to start the reaction. The non-energy-linked transhydrogenase (----) has not been subtracted, and is not affected by inhibitors. A, Aurovertin; *, oligomycin A; Ei, DCOD.
inhibitors on' the ATPase activity of HBHM(N) induced by the uncoupling agent 4,5,6,7-tetrachloro-2-trifluoromethylbenzimidazole (Beechey, 1966) are shown in Fig. 4 . Maximum inhibition, usually greater than 85%, of the ATPase activity is observed in the presence of 0-6nmole of oligomycin A/mg. of protein or 0-45nmole of DCCD/mg. of protein. In contrast with this, the maximum inhibition caused by aurovertin is just over 50%, and this at 50nmoles/mg. of protein. Fig. 1 . Inhibition of the ADP-stimulated respiration of mitochondria. Different amounts of DCCD dissolved in ethanol were added to 1 ml. samples ofHBHM(N) containing 30mg. of protein. The mitochondria, which were suspended in 0-25m-sucrose-10mM-tris sulphate, pH7.7, were incubated at 0°overnight. Untreated HBHM(N) were also stored overnight at 0°and used for experiments with aurovertin and oligomycin A, which were added at the time of assay. Respiration rates were measured in an oxygen electrode: 0.1 ml. of mitochondrial suspension was added to an air-saturated reaction mixture containing (final conens.) 0-25M-sucrose, 7.5mM-potassium phosphate buffer, pH7-4, l0mM-MgSO4, 2.5mm-potassium L-glutamate, 2-5mm-potassium L-malate and 5mM-potassium malonate. Aurovertin or oligomycin was added as a solution in less than 5 ,u. of ethanol. The total volume was 4-16ml. and the temperature 300. The respiration rate was measured for 3min., and then 20pl. of 40mm-ADP was added and the respiration rate was measured again. The differences between the respiration rates in the presence of ADP (state 3; Chance & Williams, 1955) Conen. of inhibitor (nmoles/mg. of protein) Fig. 4 . Inhibition of 4,5,6,7-tetrachloro-2-trifluoromethylbenzimidazole-stimulated ATPase in HBHM(N). DCCD was preincubated overnight with the mitochondria. Aurovertin and oligomycin A were incubated with the mitochondria in the assay cuvette, as described below.
NLitochondria (0-3mg. of protein) were preincubated at 300 for 3min. in a solution containing 0-25m-mole of sucrose, 25jumoles of tris sulphate buffer, pH7.4, 0-3,umole of NADH, 1,tmole of KCN, 50, ug. of lactate dehydrogenase, 25,g. of pyruvate kinase and inhibitors at various concentrations in a volume of 0-84ml. After 3min. 0-1 nmole of 4,5,6,7-tetrachloro-2-trifluoromethylbenzimidazole was added. After a further 0-5min. a prewarmed solution containing 2,umoles of ATP, 2,umoles of MgSO4, 2 jmoles of phosphoenolpyruvate and 501,moles of tris sulphate buffer, pH 7-4, in 0-16ml. was added to start the reaction. The NADH oxidation was followed spectrophotometrically.
A, Aurovertin; e, oligomycin A; El, DCCD.
Effects of inhibitors on EDTA-particles Oligomycin A and DCCD stimulation of ATPdriven reduction of NAD+ by succinate in EDTAparticles. The observation that P/O ratios and ATP-driven reduction of NAD+ by succinate may be stimulated in EDTA-particles by the addition of low concentrations of oligomycin, rutamycin or DCCD has been made in many Laboratories (Lee & Ernster, 1965; Fessenden & Racker, 1966; Lam, Warshaw & Sanadi, 1966; Beechey et al. 1967a ). Some typical results, showing the effect of adding low concentrations of inhibitors to EDTA-particles, are shown in Fig. 5(a) . The EDTA-particles used in this experiment were prepared from HBHM(B). The control rate of ATP-driven reduction of NAD+ by succinate, 6nmoles of NAD+ reduced min.-1 mg.-1 ofprotein, is stimulated to a maximum rate of 18nmoles of NAD+ reduced min. Oligomycin A always gives a greater stimulation than DCCD. Aurovertin is not able to stimulate the reaction, and exhibits its normal inhibitory pattern (cf. Fig. 2 ). Another typical experiment of this type is shown in Fig. 5(b) . The difference from the above experiment is that the EDTAparticles were prepared from HBHM(N). The control rate of ATP-driven reduction of NAD+ by succinate in these EDTA-particles (9nmoles min. The results of a series of such experiments are shown in Table 1 . Three trends may be discerned in the results. First, EDTA-particles prepared from HBHM(N) require higher concentrations of inhibitors for maximal stimulation (0-3-0-6nmole of inhibitor/mg. of protein) than EDTA-particles prepared from HBHM(B) (0-2-0-3nmole of inhibitor/mg. of protein). Secondly, the average percentage stimulation (505%) and the maximal stimulated rates are greater in the EDTA-particles -derived from HBHM(N) than in the EDTAparticles from HBHM(B), which were stimulated on an average by 250%. Thirdly, as mentioned above, oligomycin A always gives a greater stimulation than DCCD. The haem a content of both preparations of EDTA-particles is the same, precluding any explanation of the first two of these phenomena on the lines that one preparation is richer in respiratory-chain content than the other.
Summation of the effect8 of DCCD and oligomycin A. Assay conditions were the same as those described in Fig.  3 . In each assay, 1-06mg. of protein of particles was used.
A, Aurovertin; *, oligomycin A; [], DCCD. preparation to which oligomycin was added. The concentration of DCCD or of oligomycin A needed for maximal stimulation is similar to the concentration required to stimulate ATP-driven reduction of NAD+ by succinate in the same preparation (results in Table 1 , Expt. 9). Aurovertin has no stimulatory effect on the ATPdriven energy-linked nicotinamide nucleotide transhydrogenase, though a marginal inhibitory effect was observed at 5nmoles of aurovertin/mg. of protein (cf. Fig. 3 ).
Effect of aurovertin, DCCD and oligomycin A on the aerobic energy-linked nicotinacnide nucleotide transhydrogenase in EDTA -particles. Lee & Ernster (1965) have shown that the rate of the aerobic energy-linked nicotinamide nucleotide transhydrogenase driven by succinate oxidation in EDTAparticles is stimulated by oligomycin A. The oligomycin was thought to prevent the breakdown of mycin-sensitive wasteful reaction. They implied that the minimum amount of oligomycin required for maximum stimulation of the aerobic energylinked nicotinamide nucleotide transhydrogenase would be the amount that maximally stimulates ATP-driven energy-linked reactions or P/O ratios in EDTA-particles. Fig. 7 (Table 4) showed that aurovertin was unable to interfere with the effect of oligomycin at the site at which the latter stimulated.
Effect of inhibitor8 on mitochondrialfactor8 a88ociated with oxidative pho8phorylation
The experiments discussed so far were carried out with HBHM, SMP or EDTA-particles. However, a number of factors have been isolated from mitochondria that are thought to be associated with the oxidative-phosphorylation process (for a review see Racker, 1965) . We therefore examined whether the actions of these inhibitors on an intact oxidativephosphorylation sequence could be correlated with their actions on the isolated factors.
Effect of DCCD on F1. A soluble ATPase resembling the coupling factor Fl was isolated from mitochondria by Selwyn (1967) . It shows all the expected interactions with CFo (Roberton et al. 1967) , the factor that confers oligomycin sensitivity on Fl (Kagawa & Racker, 1966b) . It has been shown previously that, though oligomycin A has no effect on Fl alone (Racker, 1962) or on Selwyn's (1967) soluble ATPase alone (Roberton et al. 1967) , aurovertin inhibits the soluble ATPase by 60-70% (Kagawa & Racker, 1966a; Roberton et al. 1967 ATPase activities were measured as described by Roberton et al. (1967) . Oligomycin A (5nmoles), Sigma soya-bean phospholipid in micellar form (Fleischer & Klouwen, 1961) Table 6 . Properties of DCCD-treated CFo Assay conditions were similar to those described in Table 5 . Effect of DCCD on CFo. Kagawa & Racker (1966b) have demonstrated that the site of oligomycin inhibition on an ATPase system containing F1, CFo and phospholipid is on the CFo complex.
It was therefore decided to see whether DCCD acts on the CFo complex. The properties of a CFo preparation, isolated from T-particles that were treated with DCCD, are described in Table 6 . Both the CFo from the DCCD-treated preparation (DCCD-CFo) and the control CFo inhibited the activity of soluble ATPase. The addition of phospholipid, however, stimulated the DCCD-CFo + soluble ATPase activity by only 32%; oligomycin A did not inhibit this activity. In contrast, the ATPase activity of the ATPase + control CFo mixture was stimulated by 170% by phospholipid. It is concluded from these results that (1) DCCD does not prevent the binding of CFo to soluble ATPase; (2) DCCD does not prevent the inhibition of the soluble ATPase activity by CFo; (3) DCCD prevents the phospholipid stimulation of the CFO+soluble ATPase system; (4) DCCD has an irreversible effect on CFo, since the DCCD effect was not lost during the preparation of CFo from T-particles (cf. , in contrast with the reversible binding of oligomycin D (Kagawa & Racker, 1966b) ; (5) DCCD has similar effects to oligomycin A in the CFo complex. Similar results to these, with an authentic F1 preparation kindly sent to us by Professor E. Racker, have already been briefly reported . These observations with DCCD and oligomycin A are quite different from those made with aurovertin, which has been shown to act on F1 or the soluble ATPase itself, as discussed above. Table 7 are listed the concentrations of DCCD, oligomycin and aurovertin that give 50% inhibition of (a) ATP synthesis (see also Fig. 1 ) and (b) the sequence working in the reverse direction, i.e. the ATP-driven energy-linked reactions (see also Figs. 2 and 3) and the uncoupler-stimulated ATPase (see also Fig. 4 ). There is a marked difference between the effects of DCCD and oligomycin on the one hand and aurovertin on the other. Aurovertin is the most potent inhibitor of ATP synthesis and the least potent inhibitor of the ATP-utilizing systems.
The concentrations of DCCD and oligomycin that give 50% inhibition of the above reactions lie within the same range, 0-21-0-75nmole of inhibitor/ mg. of protein (Table 7) , DCCD being always marginally less potent than oligomycin A. The variation in potencies of DCCD and oligomycin A for the different reactions may be a reflection of the affinity of these reactions for the high-energy intermediate whose formation or utilization is blocked by the inhibitor. This explanation is similar to that given by Danielson & Ernster (1963) , who suggested that 2,4-dinitrophenol was a more potent inhibitor of the ATP-driven reduction of NAD+ by succinate than of the ATP-driven energy-linked nicotinamide nucleotide transhydrogenase because the former reaction must have a lower affinity for the common high-energy intermediate whose hydrolysis is mediated by 2,4-dinitrophenol. It can be seen from the data in Table 7 that the potencies of DCCD and oligomycin A vary in a parallel manner, suggesting that they inhibit the formation or utilization of the same intermediate. This conclusion is supported by the data in Table 2 , where it is shown that the stimulatory properties of DCCD and oligomycin A are additive. In contrast, the data in Table 7 show that the concentrations of aurovertin that inhibit the listed reactions do not parallel those of DCCD and oligomycin A. A 50% inhibition of ADP-stimulated However, aurovertin is a less potent inhibitor than either DCCD or oligomycin A of the reverse sequence of oxidative phosphorylation, the ATPdriven reactions. The ATP-driven reduction of NAD+ by succinate is 50% inhibited by 0-95nmole of aurovertin/mg. of protein ( Fig. 2 and Lenaz (1965) found that this system was even less sensitive to aurovertin (43% inhibition by 4-2nmoles/mg. ofprotein). The ATP-driven energylinked nicotinamide nucleotide transhydrogenase is 50% inhibited by 3-Onmoles of aurovertin/mg. of protein ( Fig. 3 and Table 7 ), a much greater concentration than is required to inhibit the forward reaction. This result also differs from that of Lenaz (1965) who found that this system was inhibited by neither 4-2 nor 420nmoles of aurovertin/mg. of protein. In our hands these concentrations ofaurovertin gave 60% and 80% inhibition. We cannot explain this difference in results. Since Lenaz (1965) found that the ATP-driven reduction of NAD+ by succinate isinhibited byaurovertin, it is not surprising that the ATP-driven energy-linked nicotinamide nucleotide transhydrogenase is inhibited. The uncouplerstimulated ATPase of mitochondria is another example of a reaction involving the reversal of the oxidative-phosphorylation sequence which is relatively insensitive to aurovertin. The 4,5,6,7-tetrachloro -2 -trifluoromethylbenzimidazolestimulated ATPase of mitochondria is 50% inhibited by 40nmoles of aurovertin/mg. of protein (Fig. 4 and Table 7), and higher concentrations of aurovertin did not give significantly greater inhibitions. This result is similar to those obtained with the aurovertin inhibition of a soluble ATPase isolated from mitochondria (Kagawa & Racker, 1966a; Roberton et al. 1967) . The results illustrated in Fig. 4 are qualitatively similar to those of Lardy (1960) and Lardy et al. (1964) , who showed that oligomycin gave more than 90% inhibition of the 2,4-dinitrophenol-stimulated ATPase activity of rat liver mitochondria, whereas high concentrations of aurovertin gave only 70% inhibition.
A comparison of the data shown in Fig. 7 and Table 1, Expt. 5 (which refer to the same particle preparation), shows that the minimum amounts of DCCD or oligomycin A required to give maximal stimulation of the aerobic energy-linked nicotinamide nucleotide transhydrogenase in EDTA-particles, i.e. 1*0 and 0.6nmole/mg. of protein for DCCD and oligomycin respectively, can be several times greater than the amounts needed to give maximum stimulation of ATP-driven reduction of NAD+ by succinate. This result differs from those of experiments described by Lee & Ernster (1965) , who found that the P/O ratios, the ATP-driven reduction of NAD+ by either succinate or ascorbate plus NNN'N' -tetramethyl -p -phenylenediamine and the aerobic energy-linked nicotinamide nucleotide transhydrogenase were all stimulated maximally by the same concentration of oligomycin, 0-3-0.4nmole/mg. of protein in EDTA-particles. We feel that our obervations are more consistent with the hypothesis put forward by Lee & Ernster (1965) that oligomycin acts preferentially at the damaged sites in EDTA-particles that lead to the hydrolysis of X I (a hypothetical non-phosphorylated highenergy intermediate in the synthesis of ATP), and that at somewhat higher concentrations oligomycin also acts at the intact sites that lead to the phosphorolysis of X I, normally leading to the formation of X , P (a hypothetical phosphorylated highenergy intermediate in the synthesis of ATP). Stimulation by oligomycin or DCCD of the partial reactions of oxidative phosphorylation is thought to be due to the inhibitors' increasing the steadystate concentration of X I. In the aerobic energylinked nicotinamide nucleotide transhydrogenase, maximum concentrations of X I will be present when both the hydrolytic and phosphorolytic fissions of X I are inhibited, i.e. at high inhibitor concentrations. However, in the ATP-driven reduction of NAD+ by succinate, the X I concentration and hence the maximal stimulation will be dependent on the net effect of these reactions and will be observed when X I hydrolysis is maximally inhibited and the synthesis of X ' I from X ' P is minimally inhibited. Thus maximum stimulation of the ATP-driven reduction of NAD+ by succinate will be observed at lower concentrations ofinhibitor.
The data in Fig. 7 show that aurovertin neither inhibits nor stimulates the aerobic energy-linked nicotinamide nucleotide transhydrogenase, and the results illustrated in Figs. 5 and 6 show that aurovertin has no stimulatory effects on the ATPdriven partial reactions. Further, the results summarized in Table 3 show that aurovertin does not affect the optimum concentration of oligomycin needed to stimulate the ATP-driven reduction of NAD+ by succinate. These observations suggest that aurovertin, unlike oligomycin A or DCCD, has no effect on the hydrolysis of X I. Since oligomycin can still stimulate the aerobic energy-linked nicotinamide nucleotide transhydrogenase in the presence of aurovertin ( Table 4 ) it follows that the sites of DCCD and oligomycin A action are nearer to the respiratory chain than the site of aurovertin inhibition (see Scheme 1).
A more direct approach to the differences in the sites of action of inhibitors in the oxidativephosphorylation sequence is to study the effects of the inhibitors on the properties of various mitochondrial fractions thought to be involved in the synthesis of ATP. Racker (1962) has shown that the ATPase activity of F1 is not inhibited by oligomycin, and this has been confirmed by Roberton et al. (1967) using a mitochondrial ATPase fraction identical with F1, described by Selwyn (1962 Selwyn ( , 1967 . The data listed in Table 5 show that F1 prepared from DCCD-treated mitochondrial extracts is functionally similar to a control preparation, suggesting that DCCD does not act on this protein in the intact mitochondrion. However, it is noteworthy that Schatz, Penefsky & Racker (1967) stated that treatment of F1 with DCCD results in an inactivation of the ATPase activity with little or no effect on the coupling activity, although no experimental details were given. Kagawa & Racker (1966a) and Roberton et al. (1967) CFo isolated from DCCD-treated T-particles differs in one specific property from a control CFo preparation: the ATPase activity of an F1-DCCD-CFo complex cannot be stimulated by the addition of phospholipid (see Table 6 ). The loss of this property from CFo is noted also when the CFo has been isolated from DCCD-treated mitochondria and DCCD-treated SMP. Also, the phospholipidstimulated ATPase activity of CFo-Fl preparations isolated from DCCD-treated SMP is greatly inhibited (A. M. Roberton, C. T. Holloway, I. G. Knight & R. B. Beechey, unpublished work). Thus it would appear that the locus of DCCD action is in the CFo complex, as is that for oligomycin (Kagawa & Racker, 1966b) . Beechey et al. (1966 Beechey et al. ( , 1967a emphasized the functional similarities between DCCD and oligomycin. Some of the data presented in the present paper extend these similarities: (1) the constant ratio of the inhibitory concentrations of the two inhibitors, listed in Table 7 ; (2) the summation of the stimulatory effects of DCCD and oligomycin A, presented in Table 2 ; (3) the lack of effect of the inhibitors on F1 and the locus of inhibition being on CFo. Racker &I Horstman (1967) have shown that both oligomycin D and DCCD will enhance the efficiency of oxidative phosphorylation in ASUparticles. The latter are a type of submitochondrial particle prepared by the ultrasonic treatment of mitochondria in a dilute solution of ammonia, followed by passage down a Sephadex G-50 colunm and subsequent treatment with urea.
It has been recognized for some time that aurovertin and oligomycin act at different sites in the oxidative-phosphorylation sequence (Lardy & McMurray, 1959; Lardy, 1960) . Lardy et al. (1964) observed that aurovertin did not abolish the effect of ATP on the swelling of mitochondria stimulated by certain uncoupling agents. These workers proposed the existence of a new high-energy intermediate, W, which was responsible for the transport of water into the mitochondrion. In contrast, oligomycin inhibited all ATPase activity. On the basis of these and other observations, Lardy et al. (1964) proposed that the sites of action of oligomycin and aurovertin are as shown in Scheme l(a). Ernster et al. (1967) reinterpreted the ATPase results in view of the results of Lenaz (1965) and some new experimental data on the effects of aurovertin and oligomycin on partial reactions. These showed that aurovertin is a potent inhibitor ofreactionsinvolvingtheoxidative-phosphorylation sequence working in the forward direction and a relatively poor inhibitor of reactions involving a reversal of the oxidative-phosphorylation process. Ernster et al. (1967) proposed that the sites of action of oligomycin and aurovertin are as shown in Scheme l(b). The present results have confirmed and extended the results of Ernster et al. (1967) . Thus it is difficult to reconcile the absence of a stimulation by aurovertin on the aerobic energylinked nicotinamide nucleotide transhydrogenase, either in the presence or in the absence of oligomycin (Table 4) , with the scheme of Lardy et al. (1964) (Scheme la). However, this observation is in accord with the scheme of Ernster et al. (1967) (Scheme lb). Also, the effect of aurovertin on the ATP-driven energy-linked nicotinamide nucleotide transhydrogenase (Fig. 3) is that to be expected from the effects of inhibition by aurovertin on the ATP-driven reduction of NAD+ by succinate and also on the uncoupler-stimulated ATPase. The inhibition of F1 ATPase activity by aurovertin and the identification of CFo as the locus of both oligomycin action (Kagawa & Racker, 1966a,b) and DCCD action (Table 6 ) are in agreement with the scheme proposed by Ernster et al. (1967) .
